An Overview of the Successful Development of Loncastuximab tesirine, a PBD Based ADC Directed Against CD19 for the Treatment of Hematological Malignancies

Time: 4:15 pm

Details:

• Review the preclinical data for IND approval
• Gain an overview of manufacturing strategy
• Analyze the clinical data

Speakers: